Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 10Phase 1 9Phase NA 3Phase EARLY_PHASE1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 85Glioblastoma 82Pancreatic Neoplasms 75Glioma 65Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 54Colorectal Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 50Squamous Cell Carcinoma of Head and Neck 46Recurrence 46Ovarian Neoplasms 45Lymphoma 39Lymphoma, Non-Hodgkin 37Lymphoma, B-Cell 36Sarcoma 35Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 33Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

tislelizumab 1Taxes 1Paclitaxel 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Turcot syndrome × Clear all
NCT06305962 2026-02-19

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Radiopharm Theranostics, Ltd

Phase EARLY_PHASE1 Recruiting
30 enrolled
BreastDermatologicGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡